文献速递肺结节与肺癌

斯鲁利单抗联合化疗±HLX04一线治疗晚期非鳞非小细胞肺癌的III期试验

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2025-12-04

ASTRUM-002研究纳入642例无EGFR敏感突变或ALK/ROS1重排的局部晚期或转移性非鳞NSCLC患者,随机接受斯鲁利单抗+HLX04+化疗(A组)、斯鲁利单抗+化疗+HLX04安慰剂(B组)或化疗+双安慰剂(C组)。

要点

  • 斯鲁利单抗联合化疗较单纯化疗显著改善一线非鳞NSCLC的PFS。
  • 加用HLX04未在斯鲁利单抗联合化疗基础上进一步显著改善PFS。
  • 三组治疗相关严重不良事件发生率分别为39%、37%和24%。

核心结论

  • 斯鲁利单抗联合化疗较化疗 alone 显著延长局部晚期或转移性非鳞NSCLC患者的PFS。
  • HLX04联合斯鲁利单抗及化疗较斯鲁利单抗联合化疗未带来进一步的统计学获益。

研究设计与样本

  • ASTRUM-002为随机、双盲、多中心、III期三臂试验,在中国72家医院入组642例患者。
  • 患者年龄≥18岁且≤75岁,无EGFR敏感突变或ALK/ROS1重排,未接受过系统治疗。
  • 随机按1:1:1分配至A组(斯鲁利单抗+HLX04+化疗)、B组(斯鲁利单抗+化疗+HLX04安慰剂)或C组(化疗+双安慰剂)。
  • 主要终点为盲态独立中心评审按RECIST v1.1评估的意向治疗人群PFS。

主要发现

  • 治疗相关严重不良事件发生率:A组39%(82例)、B组37%(79例)、C组24%(51例)。
  • ≥3级治疗相关不良事件发生率:A组71%(149例)、B组66%(142例)、C组57%(119例)。

关键数值与推荐

  • 治疗相关不良事件导致死亡:A组5%(10例)、B组2%(5例)、C组3%(7例)。

临床怎么用

  • 对于无EGFR敏感突变或ALK/ROS1重排的局部晚期或转移性非鳞NSCLC,斯鲁利单抗联合化疗可作为一线治疗选择。
  • 不推荐在斯鲁利单抗联合化疗基础上常规加用HLX04,因未显示进一步PFS获益。

局限性

  • 研究仅在中国进行,纳入人群以男性(73%)和汉族(94%)为主,外推性需谨慎。
  • 总生存期数据未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether the addition of bevacizumab to a programmed cell death protein-1 (PD-1) inhibitor plus chemotherapy can provide further survival benefits as first-line treatment in non-squamous non-small-cell lung cancer (NSCLC) without EGFR sensitising mutations, or ALK/ROS1 rearrangements, is unknown. We evaluated serplulimab (an anti-PD-1 antibody) plus HLX04 (a bevacizumab biosimilar) and chemotherapy in non-squamous NSCLC. METHODS: ASTRUM-002 is a randomised, double-blind, multicentre, phase 3 trial with a three-arm design. Patients (aged ≥18 years and ≤75 years) with locally advanced or metastatic non-squamous NSCLC without EGFR sensitising mutations or ALK/ROS1 rearrangements and previous systemic therapy were randomly assigned (1:1:1; stratified by PD-L1 expression, smoking history, and brain metastasis) to receive serplulimab (4·5 mg/kg intravenously) plus HLX04 (15 mg/kg intravenously) and chemotherapy (pemetrexed and carboplatin; group A), serplulimab plus chemotherapy plus HLX04 placebo (group B), or chemotherapy plus serplulimab placebo plus HLX04 placebo (group C). The primary endpoint was the blinded independent central review assessed progression-free survival per the Response Evaluation Criteria in Solid Tumors version 1.1, assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03952403, and is complete. FINDINGS: Between Nov 25, 2019, and June 15, 2022, 642 patients were enrolled across 72 hospitals in China; six in the safety run-in phase and the remaining 636 patients were randomised to group A (212 patients), B (214), or C (210). 465 (73%) were male, 171 (27%) were female, and 599 (94%) were of Han ethnicity. By the data cutoff date of June 15, 2023, the median follow-up duration was 23·4 months (95% CI 21·6-24·9) in group A, 23·1 (21·4-25·6) in group B, and 23·0 (20·7-25·6) in group C. Median progression-free survival was 12·6 months (95% CI 8·7-14·0; 123 events) in group A, 11·0 months (95% CI 8·4-12·7; 130 events) in group B, and 5·6 months (95% CI 4·8-6·8; 156 events) in group C. A significant reduction was seen in risk of progressive disease or death for patients in group B compared with group C (hazard ratio [HR] 0·55, 95% CI 0·43-0·69; p<0·0001). No significant improvement in progression-free survival was seen for group A compared with group B (HR 0·86, 0·67-1·11; p=0·25). Treatment-related serious adverse events occurred in 82 (39%) patients in group A, 79 (37%) in group B, and 51 (24%) in group C. Grade 3 or worse treatment-related adverse events occurred in 149 (71%) patients in group A, 142 (66%) in group B, and 119 (57%) in group C. Treatment-related adverse events leading to death occurred in ten (5%) patients in group A, five (2%) in group B, and seven (3%) in group C. INTERPRETATION: The addition of serplulimab to chemotherapy led to significantly longer progression-free survival in patients with locally advanced or metastatic non-squamous NSCLC compared with chemotherapy alone and represents an alternative first-line treatment option for this patient population. HLX04 plus serplulimab and chemotherapy did not confer further statistical benefit compared with serplulimab plus chemotherapy. FUNDING: Shanghai Henlius Biotech.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Wang L, Hao X, Hao Y, et al. First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial. Lancet Respir Med. 2025. PMID: 41354044. doi:10.1016/S2213-2600(25)00263-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。